Product Description
novel recombinant human/mouse chimeric epidermal growth factor receptor (EGFR) monoclonal antibody
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Zhangjiang Biotechnology Limited Company
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
009mCRCIIIP | P3 |
Active, not recruiting |
Colorectal Cancer |
2022-05-06 |
34% |